During the past decade, Summit Headache and Neurologic Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Summit Headache and Neurologic Institute" are "Migraine" (1 trials) and "Migraine, With or Without Aura" (1 trials). Many other conditions were trialed in "Summit Headache and Neurologic Institute" in a lesser frequency.

Most popular intervention types in "Summit Headache and Neurologic Institute" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Erenumab" (1 trials), "Placebo" (1 trials), "Placebo-matching Ubrogepant" (1 trials), "Ubrogepant" (1 trials) and "Usual Care" (1 trials). Other intervention names were less common.

The vast majority of trials in "Summit Headache and Neurologic Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Summit Headache and Neurologic Institute". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Summit Headache and Neurologic Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Summit Headache and Neurologic Institute, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".